bausch & lomb corp - BLCO

BLCO

Close Chg Chg %
17.45 -0.15 -0.86%

Closed Market

17.30

-0.15 (0.86%)

Volume: 254.88K

Last Updated:

Jan 14, 2026, 3:59 PM EDT

Company Overview: bausch & lomb corp - BLCO

BLCO Key Data

Open

$17.39

Day Range

17.30 - 17.59

52 Week Range

10.45 - 18.14

Market Cap

$6.20B

Shares Outstanding

354.19M

Public Float

38.07M

Beta

0.61

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.86

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

335.45K

 

BLCO Performance

1 Week
 
0.64%
 
1 Month
 
1.94%
 
3 Months
 
15.47%
 
1 Year
 
-0.23%
 
5 Years
 
N/A
 

BLCO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About bausch & lomb corp - BLCO

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

BLCO At a Glance

Bausch + Lomb Corp.
520 Applewood Crescent
Vaughan, Ontario L4K 4B4
Phone 1-905-695-7700 Revenue 4.79B
Industry Medical Specialties Net Income -317,000,000.00
Sector Health Technology 2024 Sales Growth 15.557%
Fiscal Year-end 12 / 2025 Employees 13,500
View SEC Filings

BLCO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.326
Price to Book Ratio 0.979
Price to Cash Flow Ratio 27.39
Enterprise Value to EBITDA 17.203
Enterprise Value to Sales 2.305
Total Debt to Enterprise Value 0.447

BLCO Efficiency

Revenue/Employee 354,888.889
Income Per Employee -23,481.481
Receivables Turnover 4.642
Total Asset Turnover 0.356

BLCO Liquidity

Current Ratio 1.604
Quick Ratio 1.008
Cash Ratio 0.182

BLCO Profitability

Gross Margin 54.915
Operating Margin 4.30
Pretax Margin -4.884
Net Margin -6.617
Return on Assets -2.356
Return on Equity -4.759
Return on Total Capital -2.779
Return on Invested Capital -2.78

BLCO Capital Structure

Total Debt to Total Equity 76.255
Total Debt to Total Capital 43.264
Total Debt to Total Assets 36.647
Long-Term Debt to Equity 75.143
Long-Term Debt to Total Capital 42.633
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bausch & Lomb Corp - BLCO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.77B 3.77B 4.15B 4.79B
Sales Growth
+10.35% +0.08% +10.03% +15.56%
Cost of Goods Sold (COGS) incl D&A
1.76B 1.76B 1.88B 2.16B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
415.00M 379.00M 382.00M 436.00M
Depreciation
123.00M 135.00M 142.00M 148.00M
Amortization of Intangibles
292.00M 244.00M 240.00M 288.00M
COGS Growth
+9.39% +0.23% +6.75% +14.77%
Gross Income
2.01B 2.01B 2.26B 2.63B
Gross Income Growth
+11.20% -0.05% +12.92% +16.21%
Gross Profit Margin
+53.28% +53.21% +54.61% +54.92%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.66B 1.79B 2.06B 2.43B
Research & Development
271.00M 307.00M 324.00M 343.00M
Other SG&A
1.39B 1.48B 1.74B 2.08B
SGA Growth
+10.23% +7.53% +15.41% +17.72%
Other Operating Expense
- - - -
-
Unusual Expense
29.00M 7.00M 102.00M 61.00M
EBIT after Unusual Expense
317.00M 213.00M 102.00M 145.00M
Non Operating Income/Expense
1.00M 6.00M 28.00M 33.00M
Non-Operating Interest Income
- 6.00M 15.00M 15.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 146.00M 296.00M 412.00M
Interest Expense Growth
- - +102.74% +39.19%
-
Gross Interest Expense
- 146.00M 296.00M 412.00M
Interest Capitalized
- - - -
-
Pretax Income
318.00M 73.00M (166.00M) (234.00M)
Pretax Income Growth
+9.66% -77.04% -327.40% -40.96%
Pretax Margin
+8.45% +1.94% -4.00% -4.88%
Income Tax
125.00M 58.00M 82.00M 71.00M
Income Tax - Current - Domestic
- 109.00M 3.00M 1.00M
Income Tax - Current - Foreign
90.00M 68.00M 71.00M 74.00M
Income Tax - Deferred - Domestic
(2.00M) (1.00M) 20.00M 1.00M
Income Tax - Deferred - Foreign
(72.00M) (12.00M) (9.00M) (5.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
193.00M 15.00M (248.00M) (305.00M)
Minority Interest Expense
11.00M 9.00M 12.00M 12.00M
Net Income
182.00M 6.00M (260.00M) (317.00M)
Net Income Growth
+1,111.11% -96.70% -4,433.33% -21.92%
Net Margin Growth
+4.83% +0.16% -6.27% -6.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
182.00M 6.00M (260.00M) (317.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
182.00M 6.00M (260.00M) (317.00M)
EPS (Basic)
- 0.0171 -0.7418 -0.9011
EPS (Basic) Growth
- - -4,438.01% -21.47%
-
Basic Shares Outstanding
- 350.00M 350.50M 351.80M
EPS (Diluted)
- 0.0171 -0.7418 -0.9011
EPS (Diluted) Growth
- - -4,438.01% -21.47%
-
Diluted Shares Outstanding
- 350.00M 350.50M 351.80M
EBITDA
761.00M 599.00M 586.00M 642.00M
EBITDA Growth
+2.84% -21.29% -2.17% +9.56%
EBITDA Margin
+20.21% +15.90% +14.13% +13.40%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 17.385
Number of Ratings 16 Current Quarters Estimate 0.077
FY Report Date 03 / 2026 Current Year's Estimate 0.785
Last Quarter’s Earnings 0.357 Median PE on CY Estimate N/A
Year Ago Earnings 0.531 Next Fiscal Year Estimate 1.073
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 14 11
Mean Estimate 0.08 0.16 0.78 1.07
High Estimates 0.17 0.22 0.85 1.23
Low Estimate -0.01 0.09 0.68 0.91
Coefficient of Variance 83.35 22.48 6.46 9.20

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 6 4
OVERWEIGHT 0 0 1
HOLD 10 9 10
UNDERWEIGHT 1 1 2
SELL 0 0 0
MEAN Overweight Overweight Hold

Insider Actions for Bausch & Lomb Corp - BLCO

Date Name Shares Transaction Value
Jul 29, 2025 Sam A. Eldessouky EVP and CFO 278,299 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share 3,985,241.68
Jul 29, 2025 Luc Bonnefoy President, Surgical 71,216 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share 1,019,813.12
Jul 29, 2025 Yehia Hashad EVP of R&D and CMO 116,739 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share 1,671,702.48
Jul 29, 2025 Frederick J. Munsch SVP, Controller and CAO 70,204 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share 1,005,321.28
Mar 3, 2025 Brenton L. Saunders CEO and Chairman of the Board; Director 697,156 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Brenton L. Saunders CEO and Chairman of the Board; Director 600,858 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Sam A. Eldessouky EVP and CFO 141,630 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ambrose Robert Douglas Bailey EVP & Chief Legal Officer 180,357 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ambrose Robert Douglas Bailey EVP & Chief Legal Officer 96,566 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Luc Bonnefoy President,Surgical 55,793 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Andrew J. Stewart See remarks 66,884 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Andrew J. Stewart See remarks 55,793 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Yehia Hashad EVP of R&D and CMO 60,085 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bausch & Lomb Corp in the News